Catabasis Pharma (CATB) – Major News
-
Catabasis Pharma (CATB) Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy Did Not Meet Primary Endpoint
-
Catabasis Pharma (CATB) Tops Q4 EPS by 6c
-
Catabasis Pharma (CATB) Tops Q3 EPS by 8c
-
Catabasis Pharma (CATB) Misses Q2 EPS by 1c
-
Catabasis Pharma (CATB) Tops Q1 EPS by 7c
-
Catabasis Pharma (CATB) Tops Q4 EPS by 5c
-
Catabasis Pharma (CATB) Reports Q3 Loss of $0.08/Share
-
Catabasis Pharma (CATB) Tops Q2 EPS by 3c
-
Catabasis Pharma (CATB) Misses Q1 EPS by 9c
-
Catabasis Pharma (CATB) to Reduce Workforce by 42% as Part of Restructuring
-
Catabasis Pharma (CATB) Tops Q4 EPS by 7c, Beats on Revenues
-
Catabasis Pharma (CATB) Tops Q3 EPS by 2c
-
Catabasis Pharma (CATB) Tops Q2 EPS by 8c
-
Catabasis Pharma (CATB) Tops Q1 EPS by 4c
-
Catabasis Pharma (CATB) Tops Q4 EPS by 5c
-
Catabasis Pharma (CATB) Tops Q3 EPS by 11c
-
Catabasis Pharma (CATB) Tops Q2 EPS by 4c
-
Catabasis Pharma (CATB) Announces CAT-2054 Phase 2a Missed Primary Endpoint in Hypercholesterolemia
-
Catabasis Pharma (CATB) Tops Q1 EPS by 3c
-
Catabasis Pharma (CATB) Tops Q4 EPS by 6c
-
Catabasis Pharma (CATB) Tops Q3 EPS by 9c
-
Catabasis Pharmaceuticals (CATB) IPO Opens Modestly Higher
-
Catabasis Pharmaceuticals (CATB) Files $75M IPO
Back to CATB Stock Lookup